BridgeBio Pharma, Inc. (BBIO) vs Exelixis, Inc. (EXEL)
A side-by-side comparison of BridgeBio Pharma, Inc. and Exelixis, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBIO
BridgeBio Pharma, Inc.
$66.14HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
EXEL
Exelixis, Inc.
$58.85HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — BBIO vs EXEL
growth of $100 · dividends reinvested · last 7yBBIO +140.1% (+13.3%/yr)EXEL +178.4% (+15.7%/yr)EXEL compounded faster over this window
BBIO EXEL
BBIO vs EXEL: by the numbers
- •EXEL is the larger company ($14.79B vs $12.95B market cap).
- •EXEL is profitable (35.33% net margin) while BBIO runs a net loss (-97.64%).
- •BBIO grew revenue faster over the past five years (62.61% vs 16.06% CAGR).
Metrics side by side
Valuation
| Metric | BBIO | EXEL |
|---|---|---|
| P/E ratio | N/A | 18.45 |
| Forward P/E | N/A | 16.75 |
| PEG ratio | N/A | 0.36 |
| P/S ratio | 18.17 | 6.07 |
| P/B ratio | N/A | 8.02 |
| EV / EBITDA | N/A | 14.68 |
| FCF yield | N/A | 7.83% |
Profitability
| Metric | BBIO | EXEL |
|---|---|---|
| Gross margin | 93.35% | 96.48% |
| Operating margin | -113.35% | 39.88% |
| Net margin | -97.64% | 35.33% |
| ROE | N/A | 46.68% |
| ROIC | -62.14% | 37.87% |
Growth (annualized)
| Metric | BBIO | EXEL |
|---|---|---|
| Revenue CAGR (5Y) | 62.61% | 16.06% |
| EPS CAGR (5Y) | N/A | 51.51% |
| FCF CAGR (5Y) | N/A | 39.63% |
| Total return CAGR (5Y) | 7.38% | 23.00% |
Frequently asked
- Which has grown faster, BBIO or EXEL?
- Over the past five years, BBIO grew revenue faster — BBIO at a 62.61% CAGR versus EXEL at 16.06%.
- Is BBIO or EXEL more profitable?
- EXEL runs the higher net margin — BBIO at -97.64% versus EXEL at 35.33%.
- How have BBIO and EXEL total returns compared?
- Over the past 5 years, BBIO delivered 7.38% and EXEL delivered 23.00% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Exelixis P/E ratioBridgeBio Pharma ROEExelixis ROEBridgeBio Pharma operating marginExelixis operating marginBridgeBio Pharma revenue growthExelixis revenue growthBridgeBio Pharma free cash flowExelixis free cash flow
BridgeBio Pharma & Exelixis appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.